Search clinical trials for: SGLT2

Total 298 results

Peking Union Medical College Hospital

Unknown

Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Northwell Health

Withdrawn

The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

Diabetes | SGLT-2 Inhibitors | Advanced Glycation End Products
Jiangsu HengRui Medicine Co., Ltd.

Completed

The PK/PD Study of Single Dose of SHR3824 in Healthy Volunteers (SHR3824)

Type 2 Diabetes

China
Samsung Medical Center

Not yet recruiting

The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction (ENRICH-PEF)

Heart Failure, Preserved Ejection Fraction

Korea, Republic of
Jiangsu HengRui Medicine Co., Ltd.

Completed

Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus
Nahla H Tohami

Unknown

Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic Patients

Diabetic Nephropathies

Egypt
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis

Type 1 Diabetes | Type 2 Diabetes

United States
University of Colorado, Denver
University of Michigan; Brigham and Women's Hospital; Boston Medical Center

Recruiting

Renal Mechanism of SGLT2 Inhibition

Diabetic Kidney Disease | Type 2 Diabetes

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

The PK/PD Study of Multiple Dose of SHR3824 in Healthy Volunteers

Type 2 Diabetes

China
Columbia University

Completed

SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy

Transthyretin Amyloid Cardiomyopathy

United States
Samsung Medical Center

Recruiting

SGLT2 Inhibitor for Severe Tricuspid Regurgitation (Reduction-TR)

Tricuspid Regurgitation

Korea, Republic of
University of Patras

Active, not recruiting

SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers (SGLT2HgB)

Diabetes Mellitus, Type 2

Greece
Ananda Basu, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); DexCom... and other collaborators

Completed

SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus (CiQ-SGLT2)

Type 1 Diabetes

United States
University of Milan

Not yet recruiting

Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients (SOLDMiDiab02)

Type2Diabetes

Italy
Mackay Memorial Hospital

Unknown

The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin

Type2 Diabetes

Taiwan
Assiut University

Not yet recruiting

Effect of Sodium Glucose Cotransporter 2 Inhibitiors on Left Ventricular Remodeling Among Diabetic and Non Diabetic Patients With Chronic Heart Failure

Chronic Heart Disease | SGLT2 Inhibitiors Remodeling Effect
Kurume University

Unknown

Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors

Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications

Japan
Woman's
AstraZeneca

Completed

EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

Obesity | Polycystic Ovary Syndrome

United States
Mansoura University

Active, not recruiting

Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients

Lupus Nephritis | SLE | SGLT2 Inhibitors

Egypt
Mansoura University

Active, not recruiting

SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients

Lupus Nephritis | BMD | SGLT2 INHIBITORS

Egypt
China National Center for Cardiovascular Diseases

Recruiting

Dapagliflozin Therapy In Cardiac Surgery

Diabetes Mellitus, Type 2 | Cardiac Surgery

China
Mario Negri Institute for Pharmacological Research
Boehringer Ingelheim

Withdrawn

SGLT2 Inhibitors in Glomerular Hyperfiltration (EMPATHY)

Obesity | Non-diabetic Chronic Kidney Disease
University of California, San Francisco

Not yet recruiting

Long Term Clinical Efficacy of Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitor in Cystinurics

Cystinuria

United States
Chungbuk National University Hospital

Completed

Head-to-head Comparison of Empagliflozin and Dapagliflozin

Type2 Diabetes

Korea, Republic of
Hannover Medical School
Boehringer Ingelheim

Terminated

SGLT2 Inhibition and Left Ventricular Mass (EMPATROPHY)

Diabetes Mellitus Type 2

Germany
Beth Israel Deaconess Medical Center
Janssen Scientific Affairs, LLC

Completed

Mechanisms of Weight Loss With SGLT2 Inhibition

Obesity | Overweight | Type 2 Diabetes

United States
Chiang Mai University

Completed

Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor

Diabetes Mellitus, Type 2 | Ischemic Heart Disease

Thailand
University Health Network, Toronto
Sunnybrook Health Sciences Centre; MOUNT SINAI HOSPITAL

Recruiting

DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk (DAPA-SWEET)

Cardiovascular Risk Factor

Canada
Stanford University
Merck Sharp & Dohme LLC

Active, not recruiting

Ertugliflozin: Cardioprotective Effects on Epicardial Fat

Cardiovascular Diseases | Atherosclerosis | Insulin Resistance | Type 2 Diabetes

United States
Nanfang Hospital of Southern Medical University

Completed

Dapagliflozin Efficacy and Action in PCOS (DEAP)

Polycystic Ovary Syndrome

China
Astellas Pharma Inc

Completed

Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Japan
Astellas Pharma Inc

Completed

A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Japan
University Health Network, Toronto
AstraZeneca; University of Toronto; Toronto General Hospital

Completed

Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects (TRANSLATE)

Focal Segmental Glomerulosclerosis

Canada
Mackay Memorial Hospital

Completed

Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial (ELUCIDATE)

Type 2 Diabetes Mellitus

Taiwan
Astellas Pharma Inc

Completed

A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
National Cheng-Kung University Hospital

Completed

SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity

Fatty Liver Disease

Taiwan
Shanghai 10th People's Hospital

Recruiting

SGLT2 Inhibitors in Treating Patients With PCOS

Polycystic Ovary Syndrome

China
Amsterdam UMC, location VUmc

Completed

SGLT2 Inhibition: Uric Acid Excretion Study (UREX)

Type 2 Diabetes

Netherlands
Shanghai Zhongshan Hospital

Recruiting

Canagliflozin and Myocardial Micro-perfusion

Cardiovascular Diseases | Type 2 Diabetes | Cardiac Perfusion Defect

China
Hongchang Guo

Recruiting

Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery

Diabetes Mellitus, Type 2 | Cardiac Surgery

China
Shanghai 10th People's Hospital

Completed

SGLT2 Inhibitors in Patients With PCOS (PCOS)

Polycystic Ovary Syndrome

China
Centre Hospitalier Universitaire de Nice

Recruiting

SGLT2 for Heart Failure in CHD Patients (GACH)

Heart Failure

France
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Doris...

Recruiting

SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

Type2 Diabetes | Heart Failure With Preserved Ejection Fraction

United States
Fondazione Schena
University of Bari

Recruiting

Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. (CLIgAN)

Glomerulonephritis | Immunoglobulin A Nephropathy

Italy
The University of Hong Kong
Food and Health Bureau, Hong Kong

Completed

Effect of Empagliflozin on Liver Fat in Non-diabetic Patients

Non-alcoholic Fatty Liver Disease

Hong Kong
Albert Einstein Healthcare Network

Suspended

Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury (DAPA-PCI-AKI)

Acute Kidney Injury | Percutaneous Coronary Intervention

United States
Amir Moheet

Recruiting

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

Cystic Fibrosis | Cystic Fibrosis-related Diabetes

United States
Minneapolis Heart Institute Foundation

Recruiting

Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

Heart Attack | Enlarged Heart

United States
Universidade Federal do Ceara
Hospital de Messejana

Enrolling by invitation

Impact of SGLT2 Inhibitors in Heart Transplant Recipients

Transplant; Failure, Heart | Rejection Heart Transplant | Cardiac Allograft Vasculopathy

Brazil
Yiming Mu

Enrolling by invitation

To Improve the Ability of Early Screening and Diagnosis in Patients With Diabetic Nephropathy

Diabetic Kidney Disease

China

Search clinical trials for: SGLT2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations